The green light was given today by China to start clinical trials for an inhaler vaccine against Covid-19 developed by the Chinese company CanSino Biologics, was announced today by the company.
Five vaccines have already been received in China conditional licensing to market or emergency licensing, but none of them are inhalable.
The National Agency for Medical Products last month gave its conditional approval to another CanSino vaccine, paving the way for its use by the public, according to Agence France-Presse and the Athens News Agency.
The inhaled vaccine was developed jointly with the Beijing Institute of Biotechnology, CanSino said in documents submitted to the Hong Kong Stock Exchange, adding that its application for clinical trials received the green light yesterday, Monday.
However during the trials it remains to be confirmed that the vaccine is harmless and effective.
As of March 20, China had administered 74.96 million doses of vaccine Covid-19, according to the Our world in data website.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
